Comparison of Apolipoprotein E polymorphism and other atherosclerotic risk factors in two Portuguese populations: the Influence of Insularity by Lopes, Paula Alexandra et al.
803 
Brazilian Archives of Biology and Technology 
Vol.50, n. 5 : pp. 803-813 September 2007 
ISSN 1516-8913    Printed in Brazil 
 BRAZILIAN ARCHIVES OF  
BIOLOGY AND TECHNOLOGY 
  
A N  I N T E R N A T I O N A L  J O U R N A L  
 
 
 
Comparison of Apolipoprotein E Polymorphism and other 
Atherosclerotic Risk Factors in two Portuguese Populations 
- the Influence of Insularity 
 
Paula Alexandra Lopes1, Gisela Gaspar2, Patrícia Napoleão1, Maria Cristina Santos3, 
Maria Leonor Pavão4 and Ana Maria Viegas-Crespo1* 
1Centro de Biologia Ambiental and Departamento de Biologia Animal; Faculdade de Ciências; Universidade de 
Lisboa;1749-016 Lisboa - Portugal. 2Centro de Biopatologia; Laboratório de Química Clínica; Instituto Nacional 
de Saúde Dr. Ricardo Jorge; Av. Padre Cruz, 1649-016 – Lisboa - Portugal. 3Centro de Química e Bioquímica and 
Departamento de Química e Bioquímica; Faculdade de Ciências; Universidade de Lisboa; 1749-016 - Lisboa - 
Portugal. 4C.I.R.N.; Universidade dos Açores; Rua Mãe de Deus, 9500-801 - Ponta Delgada - Portugal 
 
 
ABSTRACT 
 
The main objective of this study was to investigate the apolipoprotein (apo) E genotypes in Portuguese populations 
from mainland (Lisbon city) and from San Miguel Island, Azores’ Archipelago (Ponta Delgada city) and to look for 
differences between these particular sites in apparently healthy subjects. Also, subjects with clinical diagnosis of 
atherosclerotic disease were investigated in San Miguel Island. In Lisbon, the genotypes distribution was: ε3/ε3 > 
ε3/ε4 > ε2/ε3 > ε4/ε4 while that, for Ponta Delgada and regardless the health condition, was: ε3/ε3 > ε2/ε3 > 
ε3/ε4. Within Ponta Delgada control group, females and males had distinct genotype frequencies. The most common 
atherosclerotic risk factors as body mass index, blood hypertension and serum lipid parameters, presented some 
differences among the allelic subgroups of apo E. The major conclusions were: 1) an apparent influence of 
insularity in apo E polymorphism was observed; 2) both the high risk genotypes ε2/ε2 and ε2/ε4 were not found, 
even in patients; 3) curiously, the genotypes proportion in females was not homogenous among the three groups.  
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INTRODUCTION 
 
Apolipoprotein E (apo E), an arginine-rich 
glycoprotein with 299 amino acids, is an integral 
surface component of chylomicrons, very-low 
density lipoproteins (VLDL), and some subclasses 
of high-density lipoproteins (HDL) (Hagberg et 
al., 2000; Lin and Kao, 2003; Leon et al., 2004). 
Its primary function is as a ligand for receptor-
mediated uptake of triglyceride-rich lipoproteins, 
but it also modulates the activity of several lipid-
metabolizing enzymes, including lipoprotein 
lipase, lecithin cholesterol acyl transferase, and 
cholesterol ester transferase (Leon et al., 2004). In 
addition, it appears to be involved with reverse 
cholesterol transport by HDL (Mahley, 1988; Leon 
et al., 2004). Apo E gene expression affects (more 
than any other gene identified so far) the 
cholesterol metabolism (Eichner et al., 2002; 
Bhakdi, 2003) and is thought to account for about 
10% of the interindividual variation in total serum 
cholesterol concentration (Stengard et al., 1996; 
Ballantyne et al., 2000). The genomic organization 
of apo E is similar to that of the apo A and apo C 
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gene families, suggesting that these genes may 
share a common ancestor (Rall et al., 1982; 
Hagberg et al., 2000). Apolipoprotein E is 
primarily synthesized in the liver, but other organs 
and tissues are recognized to synthesize it, as 
brain, spleen, kidneys, gonads, adrenals, and 
macrophages (Mahley, 1988; Eichner et al., 2002). 
The structural gene locus for apo E is 
polymorphic: 3 common alleles, ε2, ε3 and ε4, 
code for 3 homozygous genotypes (ε2/ε2, ε3/ε3 
and ε4/ε4), and 3 heterozygous genotypes (ε2/ε3, 
ε3/ε4 and ε2/ε4), although other less frequent 
variants have been reported (Ehnholm et al., 1986; 
Richard et al., 1994; Yokoyama, 2004). The 
isoforms differ from each other by a single amino 
acid substitution and by their binding affinity for 
the four apo E receptors (Richard et al., 1994; 
Siest et al., 1995a). Those alleles with well known 
decreasing frequency are grouped into three major 
isoforms: apo E2 (that contains cysteine at both 
positions 112 and 158), apo E3 (contains cysteine 
at position 112 and arginine at position 158) and 
apo E4 (contains arginine at both positions 112 
and 158) (Richard et al., 1994; Siest et al., 1995a; 
Braeckman et al., 1996; Ballantyne et al., 2000). 
The apo E gene polymorphism has also a strong 
prediction effect on the level of its gene products: 
ε2 is associated with higher concentrations of apo 
E and ε4 with the opposite effect (Siest et al., 
1995a; Eichner et al., 2002). 
The ε2 allele, when present in homozygosity, is 
associated with type III hyperlipoproteinemia, a 
familial disorder characterized by 
hypertriglyceridemia and hypercholesterolemia 
(Hui et al., 1984; Mahley et al., 1984), while the 
ε4 allele has been prospectively associated with 
pathological conditions, as coronary artery disease, 
ischemic heart disease, stroke, postoperative 
cognitive dysfunction and Alzheimer´s disease 
(Roses, 1998; Vincent-Viry et al., 1998; Dreon 
and Peroutka, 2001; Shea et al., 2002), since 
promotes elevated levels of both total cholesterol 
and LDL-cholesterol in plasma (Mahley et al., 
1984; Mahley, 1988). The most usual 
pathophysiological feature explaining these 
positive clinical associations, mainly with the ε4 
allele, has been proposed to be associated with 
decreased endogenous antioxidant capability 
(Peroutka and Dreon, 2000; Shea et al., 2002) and 
several recent studies support the hypothesis that 
pathological conditions mostly associated with this 
allele can be moderated by antioxidant therapies, 
such as vitamin E administration (Dreon and 
Peroutka, 2001). In the past, neither predictive nor 
diagnostic genetic testing for genes susceptibility 
(e.g. apolipoprotein E, apolipoprotein B) were 
encouraged, but in the last few years, various 
authors have proposed the clinical utility of 
individual’s apo E allelic profile determination as 
a strategy to identify patients at high risk of some 
oxidative damage-associated diseases (Siest et al., 
1995a; Dreon and Peroutka, 2001). The 
atherosclerosis is a typical case. In recent years, 
the apo E polymorphism has been not only 
associated with lipid metabolism, as previously 
referred but also with blood coagulation and 
endothelial function which are known to play an 
important role in atherosclerosis development 
(Andreassi, 2003). It is well recognized the crucial 
role of apo E in the transport of lipoproteins and 
thus its involvement in several arterial wall 
processes (Slooter et al., 2001), wherein oxidative 
stress conditions might be involved. The presence 
of functional allelic variations may determine 
individual’s susceptibility for the manifestation of 
atherosclerosis, depending on the interaction with 
other factors such as other genes, dietary habits 
and/or environmental factors (Andreassi, 2003; 
Tan et al., 2003). In addition, metabolic factors 
such as obesity and blood pressure might 
constitute key components for premature 
atherosclerosis and associations with apo E 
polymorphism have been explored (de Knijff et 
al., 1994; Uusitupa et al., 1994; Siest et al., 1995a; 
Schwanke et al., 2002). 
The objectives of the present study were to 
investigate the apo E genotype distribution in 
apparently healthy Portuguese subjects living in 
two geographically apart cities, Lisbon (mainland) 
and Ponta Delgada (San Miguel Island – Azores’ 
Archipelago), in order to test the influence of 
insularity on genotyping variability and to study 
the apo E polymorphism distribution in subjects 
suffering from atherosclerosis disease, from 
Azores’ Archipelago. Other purpose was to look 
for possible relationships between apo E 
genotypes and the gender as well as the most 
current cardiovascular risk factors as body mass 
index, hypertension and lipid profile. To the best 
of our knowledge, this study was the first report 
examining apo E polymorphism in a Portuguese 
island, since Lisbon population was already 
studied during the ApoEurope Project (Schiele et 
al., 2000). 
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SUBJECTS AND METHODS 
 
Populations 
The healthy subjects (controls) were recruited in 
the National Health Institute Dr. Ricardo Jorge 
(Lisbon) and Atlantilab Laboratories (Ponta 
Delgada). Patients from Ponta Delgada with 
coronary heart disease submitted to percutaneous 
revascularization constituted the pathological 
group. All subjects gave their informed consent for 
participating in the study, which was approved by 
the ethics committee of the National Health 
Institute Dr. Ricardo Jorge. Information on health 
status, drug intake and smoking behaviour was 
obtained for each participant through a 
questionnaire. Smokers consumed on average 15 
cigarettes per day. Both body height and weight 
were registered and body mass index (BMI=ratio 
between weight and squared height, in kg/m2) was 
calculated as an index of body size used in current 
analyses. The World Health Organization reported 
the following categories for BMI: obese (≥ 30 
kg/m2), overweight (25.0-29.9 kg/m2), normal 
(18.5-24.9 kg/m2) and underweight (<18.5 kg/m2) 
(Expert Panel, 1998). Systolic and diastolic blood 
pressures were measured to the nearest mm Hg. 
Hypertension was defined according to the 
recommendations of the National Institutes of 
Health (systolic blood pressure > 140 mm Hg 
and/or diastolic blood pressure > 90 mm Hg or 
under antihypertensive therapy) (Santos and 
Barros, 2003). 
 
Laboratory analysis 
Blood collection 
Subjects were fasted overnight and blood samples 
were taken in the morning into vacutainer tubes, 
containing EDTA for DNA extraction and no 
additives for serum. For DNA extraction, samples 
were stored at -70ºC until analyses. Serum was 
separated after centrifugation at 1500 g for 10 
minutes at 4ºC and the determinations of lipids 
concentrations carried out at once. 
 
Lipid profile evaluation 
Separation of HDL lipoproteins was obtained by 
adding polyethylene glycol to the fresh samples in 
order to precipitate other lipoproteins (Ballantyne 
et al., 1982). Enzymatic methods were applied to 
assay total cholesterol, HDL-cholesterol and 
triglycerides concentrations in serum, using 
CHOD-PAP, HDL-C Plus and GPO-PAP 
analysis kits, respectively (Roche Diagnostics, 
Manheim, Germany). LDL-cholesterol 
concentration was estimated by the original 
Friedewald formula (Friedewald et al., 1972).  
 
Apo E genotyping 
DNA extraction was performed following the 
method of Miller et al. (1988). Briefly, the 
genotyping procedure uses the Polymerase Chain 
Reaction (PCR) to amplify the apolipoprotein E 
gene sequences containing amino acid positions 
112 and 158. The amplification products were then 
submitted to digestion with the restriction enzyme 
Hha I, as described elsewhere (Hixson and 
Vernier, 1990). Each apo E allele yields a distinct 
pattern after electroforesis on polyacrylamide gels 
(Hixson and Vernier, 1990; Richard et al., 1994).  
 
Data analysis 
The statistical analysis was performed using 
GenePop 3.4 and Statistica 5.0 softwares. Apo E 
allele frequencies were estimated using the gene-
counting method and a χ2-goodness-of-fit test was 
applied to evaluate the genetic Hardy-Weinberg 
equilibrium (Guo and Thompson, 1992) for the 
apo E polymorphism. The differences in apo E 
allele frequencies between the study groups were 
tested using a χ2-association test. Three subgroups 
were created corresponding to E2-, E3- and E4-
containing genotypes in order to explore the allelic 
effect and to increase statistical power (Braeckman 
et al., 1996). Carriers of the ε2 allele (ε2/ε3) were 
classified as E2, homozygotes for the ε3 allele 
(ε3/ε3) as E3 and carriers of the ε4 allele (ε3/ε4 
and ε4/ε4) as E4. Subjects with the ε2/ε2 or the 
ε2/ε4 genotypes were not found in this study. 
Normality of the other variables was tested and 
since all parameters presented normal 
distributions, no further transformations were 
carried out. A t-test was performed to compare 
means samples, being the global level of statistical 
significance set at α=0.05. 
 
 
RESULTS 
 
Populations characteristics 
Table 1 reports the descriptive statistics, according 
to the provenience, anthropometric parameters and 
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health condition. The mean age for the three 
groups was similar. The majority of individuals 
were classified as obese or overweight subjects, 
having the patients higher BMI values. 
Hypertension occurrence was more pronounced in 
patients. Concerning lipid contents, no differences 
were found between control subjects from the two 
cities (Table 1).  
 
Table 1 - Baseline characteristics for Lisbon and Ponta Delgada groups.  
Lisbon 
 
Ponta Delgada 
 
Parameters 
Control 
(n=67) 
Control  
(n=40) 
Patients  
(n=40) 
    
    
Females (%) 67 55 50 
Age (years) 54 ± 7 51 ± 7 56 ± 8 
BMI (kg/m2) 27.3 ± 4.7 26.2 ± 3.5 30.2 ± 4.6 
Systolic BP (mm Hg) 132 ± 21 129 ± 18 146 ± 21 
Diastolic BP (mm Hg) 80 ± 12 82 ± 13 89 ± 13 
Hypertension (%) 36 23 78 
    
Serum Lipids (mg/dl)    
Total Cholesterol 209 ± 37 213 ± 33 192 ± 39a 
HDL–Cholesterol 59 ± 13 57 ± 13 43 ± 8a 
LDL–Cholesterol 129 ± 34 133 ± 32 114 ± 33a 
Triglycerides 104 ± 45 101 ± 36 157 ± 62a 
Hyperlipidemia (%) 61 70 72.5 
    
Current Smoking  (%) 3 42.5 32.5 
    
Medicine intake (%)    
 Statins 3 10 77.5 
Antihypertensives 22 17.5 77.5 
Antiplatelet agents 1.5 0 82.5 
    
Data are presented as mean ± standard deviation, except otherwise indicated. aSignificant differences between the patients and control groups 
from Ponta Delgada (t-test, p<0.05). 
 
 
In Ponta Delgada, comparing serum lipids for 
control and patients, all parameters reached 
powerful statistically significance having the 
patients higher triglycerides and lower HDL-
cholesterol concentrations, in spite of lower levels 
of both total and LDL-cholesterol (probably due to 
statins treatment) (Table 1). Smokers were greatly 
represented in Ponta Delgada, being the accounts 
observed in this city identical for control and 
patients (Table 1). Results for lipid parameters, 
blood pressure and BMI were similar between 
smokers and nonsmokers within each group (data 
not shown), thus justifying no need for further 
division. As seen in Table 1, the high number of 
patients consumed drugs. Several subjects 
conjugated more than one therapy, being the 
percentages 2.5 and 4.4 for the control subjects 
from Ponta Delgada and Lisbon, respectively and 
77% for the patients. Moreover, the conjugation of 
the three therapies was only observed in the 
pathological group (55%). 
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Table 2 – Prevalence of apo E genotypes for Lisbon and Ponta Delgada groups.  
 Lisbon Ponta Delgada 
 Control Control Patients 
 n gender n gender n gender 
       
Observed frequencies       
ε2/ε3 5 2F / 3M 8 6F / 2M 5 1F / 4M 
ε3/ε3 54 39F / 15M 28 12F / 16M 31 18F / 13M 
ε3/ε4 7 4F / 3M 4 4F 4 1F / 3M 
ε4/ε4 1 1M 0 - 0 - 
χ2 statistica 2.242 1.246 0.643 
P-value 0.326 0.536 0.725 
Relative allele frequencies    
ε2 0.037 0.100 0.063 
ε3 0.896 0.850 0.888 
ε4 0.067 0.050 0.050 
    
aχ2: statistic between observed and expected values under Hardy-Weinberg equilibrium. 
 
 
Distribution of apo E genotypes  
The distribution of apo E genotypes for the three 
groups showed no significant departure from 
Hardy-Weinberg equilibrium (Table 2).  
Although all three alleles were represented in the 
samples, both ε2/ε2 and ε2/ε4 genotypes were not 
found (as referred before) and only one male was 
found in Lisbon with the ε4/ε4 genotype (Table 2). 
The majority of the subjects were ε3/ε3 
homozygous and the occurrence of both ε2/ε3 and 
ε3/ε4 heterozygous genotypes appeared to be 
inverted between Lisbon and Ponta Delgada 
(Table 2). For Lisbon, the largest count was for the 
ε3/ε3 genotype, with the ε3/ε4 genotype as the 
second largest, followed by the ε2/ε3 genotype and 
lastly the ε4/ε4 genotype (Table 2). For Ponta 
Delgada and regardless the health condition, the 
largest counts were for the ε3/ε3 genotype, 
followed by the ε2/ε3 genotype and finally the 
ε3/ε4 genotype (Table 2). Thus, the relative allelic 
frequency of ε3 was identical for both cities, being 
lower for ε2 and higher for ε4 in Lisbon compared 
to Ponta Delgada. 
The apo E genotypes distribution for the 
Portuguese population was proved to be similar 
between genders (χ2=2.3, dƒ=3, p=0.05). This 
trend was observed within the Lisbon (χ2=4.7, 
dƒ=3, p=0.05) and Ponta Delgada pathological 
groups (χ2=3.6, dƒ=2, p=0.05), but not in controls 
from Ponta Delgada (χ2=6.2, dƒ=2, p=0.05) (Fig. 
1; Table 2).  
A general approach confirmed that the genotypes 
proportion in males was homogenous among the 
three groups (χ2=5.7, dƒ=6, p=0.05). The same 
observation could not be applied for the female 
gender (χ2=12.4, dƒ=4, p=0.05). 
 
Distribution of body mass index, blood pressure 
and serum lipids, according to apo E genotypes 
In Table 3, body mass index, systolic and diastolic 
blood pressures and serum lipid concentrations 
according to apo E genotype subgroups, are 
presented for Lisbon and Ponta Delgada. In 
controls, either from Lisbon or from Ponta 
Delgada, the BMI was similar, but the E3 
subgroup of patients had higher BMI than its 
control (Table 3). 
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Figure 1 – Distribution of apo E genotypes by gender in both control groups. A – Lisbon; B – 
Ponta Delgada. Black lines – females; gray lines – males 
 
 
 
Table 3 – Body mass index, blood pressure and serum lipid concentrations, according to apo E genotypes subgroups 
for Lisbon and Ponta Delgada groups.  
 Lisbon Ponta Delgada 
 Control Control Patients 
Parameters E2 E3 E4 E2 E3 E4 E2 E3 E4 
 (n = 5) (n = 54) (n = 8) (n = 8) (n = 28) (n = 4) (n = 5) (n = 31) (n = 4) 
          BMI (kg/m2) 30.1 ± 2.9 26.8 ± 4.3 28.6 ± 7.6 26.1 ± 4.1 26.4 ± 3.4c 24.3 ± 2.6 29.1 ± 4.2 30.6 ± 28.5 ± 6.9 
          
Blood Pressure (mm          
Systolic BP 137 ± 4 129 ± 21 150 ± 22 123 ± 17 130 ± 18c 135 ± 21 144 ± 19 146 ± 144 ± 23 
Diastolic BP 86 ± 4f 79 ± 12a 85 ± 14 72 ± 11b,e,f 85 ± 13a,b 79 ± 14 92 ± 11e 89 ± 15 86 ± 5 
          
Serum Lipids (mg/dl)          
Total Cholesterol 193 ± 37 208 ± 35 209 ± 31 194 ± 31 218 ± 32 215 ± 38 190 ± 33 195 ± 41 168 ± 36 
HDL–Cholesterol 52 ± 9 60 ± 12 55 ± 12 58 ± 10 55 ± 14c 65 ± 11d 47 ± 12 43 ± 8c 37 ± 0.5d 
LDL–Cholesterol 120 ± 32 123 ± 28a 133 ± 23 111 ± 25b 139 ± 31a,b,c 133 ± 33 95 ± 37 118 ± 104 ± 39 
Triglycerides 111 ± 49 99 ± 39 102 ± 22 94 ± 21e 106 ± 39c 84 ± 36 160 ± 70e 159 ± 135 ± 51 
Data are presented as mean ± standard deviation. Values in each row sharing the same superscript are significantly different (t-test, p<0.05). 
 
 
Comparing the control groups from the two cities, 
the E3 subgroup from Ponta Delgada had higher 
diastolic blood pressure and LDL-cholesterol 
contents than its counterpart from Lisbon and the 
E2 subgroup showed higher values of diastolic 
blood pressure in Lisbon (Table 3). No 
discrepancies were observed for the studied 
parameters among the Lisbon subgroups (Table 3). 
For the control subjects from Ponta Delgada, E3 
subgroup presented higher values of diastolic 
blood pressure and LDL-cholesterol and also 
approached statistical significance for total 
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cholesterol (t-test, p=0.067) relative to E2 
subgroup (Table 3). Additionally, in Ponta 
Delgada E3 subgroups, values for total, HDL- and 
LDL-cholesterol were higher in control subjects in 
comparison to patients; while systolic blood 
pressure and triglycerides levels were lower (Table 
3). For E4 subgroups, HDL-cholesterol 
concentration was enhanced in control subjects in 
comparison to patients (Table 3). Patients from the 
E2 subgroup presented higher levels of diastolic 
blood pressure and triglycerides than their 
counterpart (Table 3). 
 
 
DISCUSSION 
 
The common alleles ε2, ε3 and ε4 for 
apolipoprotein E are thought to confer risk 
information for disease due to their possible 
association with interindividual variation of the 
lipid profile in both healthy and pathological 
populations (Stengard et al., 1996). 
In the present study, the Hardy-Weinberg 
equilibrium for apo E was in accordance with 
findings by Schiele et al. (2000) for Lisbon 
population and was observed for the first time for 
Ponta Delgada city from the Azores’ Archipelago. 
The Hardy-Weinberg law plays an important role 
concerning population genetics and often serves as 
a basis for genetic inference (Guo and Thompson, 
1992). In several population studies, the gene 
frequencies measured for apo E range from 0.077 
to 0.170 for ε2, from 0.720 to 0.783 for ε3, and 
from 0.110 to 0.175 for ε4 (Ehnholm et al., 1986; 
Braeckman et al., 1996; Ballantyne et al., 2000; 
Schiele et al., 2000). The frequencies of apo E 
alleles observed in our study in Lisbon and Ponta 
Delgada cities were not far from those for other 
European populations (Schiele et al., 2000), but 
the ε4 allele frequency was lower. It is known that 
the ε4 frequency in Europe is distributed along a 
decreasing north/south gradient (Siest et al., 
1995a; Siest et al., 1995b; Boer et al., 1997; 
Schiele et al., 2000). In comparison to the results 
of the ApoEurope Project (Schiele et al., 2000) 
and being aware of the huge difference in samples 
size, the relative allelic frequencies found by us for 
ε2 and ε4 in Lisbon population were inferior 
(0.037 versus 0.063 and 0.067 versus 0.097) and 
for ε3 was superior (0.896 versus 0.839). Anyway, 
through the present study, the ε3 allele was once 
more validated as the most representative in a 
population (Mahley et al., 1984; Mahley, 1988). 
Apolipoprotein E ε2/ε3 heterozygoty may have a 
protective effect on the development of early 
atherosclerosis (Menzel et al., 1983) and the 
various apo E isoforms have been suggested to 
exert different antioxidant effects (Slooter et al., 
2001). The lower ε2/ε3 frequency observed in 
Lisbon in comparison to Ponta Delgada control 
subjects implies that any protective effect towards 
atherosclerosis could be limited in mainland 
relative to the island (Slooter et al., 2001). 
Furthermore, the rare high risk genotypes were not 
found in our study (except one ε4/ε4 person), 
which agrees with studies on other populations 
(Stengard et al., 1995; Stengard et al., 1996; 
Boudreau et al., 1999). 
In Ponta Delgada the genetic variability of apo E 
appeared to be lower than in Lisbon. The 
continuous departure of Portuguese subjects from 
the nine islands of Azores’ to elsewhere 
constitutes a valid argument to take into 
consideration in this particular case. Migration 
processes can act as a possible confounding factor 
towards allelic frequencies interpretation 
(Stengard et al., 1995). As far as we know, besides 
the detachment from mainland, islands represent 
per se a powerful way of isolation, that might 
contribute to the apparently lower variability 
found in Ponta Delgada. It would be of great 
interest to determine and compare the apo E 
polymorphism in the other islands and such 
research is warranted in a near future.  
In this study, the distribution of apo E genotypes 
within Ponta Delgada control group was different 
between genders. This result could be justified, 
mainly by the ε3/ε3 genotype (the most common 
allelic profile), whose occurrence in Lisbon and 
Ponta Delgada pathological groups were higher in 
females. Furthermore, the genotypes proportion 
was not homogenous in the female gender across 
the three studied groups. These differences 
constitute novel findings, which are not in 
accordance with others (Boudreau et al., 1999) and 
require confirmation. The small sample size 
involved in this study could be considered as a 
potential misleading cause for this result (Novaro 
et al., 2003) or eventually a chance finding. 
Besides the apo E allelic profile, other 
physiological and metabolic parameters such as 
hyperlipidemia, obesity, blood hypertension and 
also, lifestyles (e.g. smoking habits), are 
Lopes, P. A. et al. 
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considered as major cardiovascular risk factors 
(Expert Panel, 2001). A relationship between apo 
E allele frequencies and known 
cardiocerebrovascular risk factors has been 
suggested (Siest et al., 1995b). The relative ε4 
allele frequency is elevated in populations with 
cardiovascular disease and also among those at 
high risk (Eggertsen et al., 1993; Stengard et al., 
1995; Stengard et al., 1996). This allele was 
associated with high serum cholesterol levels in 
two European populations but less or not 
significant in two Asian populations (Utermann, 
1987). In our study, any association between ε4 
allele and high serum cholesterol contents was not 
accomplished, in spite of a slight tendency in the 
Lisbon group. However, in a recent study 
conducted in Singapore, serum total cholesterol 
and LDL-cholesterol concentrations reached the 
highest levels in ε4 carriers and the lowest in ε2 
carriers, and the reverse effect occurred in HDL-
cholesterol levels (Tan et al., 2003). Our findings 
could be justified by the lower allelic frequency of 
ε4. 
Portugal has the highest stroke mortality rate in 
Western Europe and cardiovascular diseases cause 
around 40% of death (World Health Organization, 
2003). Obesity has become a world-wide epidemic 
(Bray and Tartaglia, 2000) and may play a role in 
disease occurrence (Carr and Brunzell, 2004), in 
particular in our country (Santos and Barros, 
2003). Actuarial tables indicate that life 
expectancy is reduced when body mass index, the 
indicator of adiposity or fatness, is significantly 
increased above certain level (BMI above 30 
kg/m2), however associations between apo E 
genotypes and obesity have not been consistent 
and no consensus has been reached so far. For 
obese individuals, an overproduction of VLDL has 
been reported (Siest et al., 1995b). VLDL are 
catabolized in part through hepatic apo B/E 
receptors and knowing the high affinity of these 
receptors for binding E4-containing lipoproteins 
and their downregulation provided by the E4 
isoform (Siest et al., 1995b), one could expect an 
accumulation of VLDL resulting in increased 
triglycerides levels in obese individuals. Alleles at 
loci coding either for the LDL receptor or for apo 
E should be included in the list of candidate genes 
determining susceptibility to metabolic 
abnormalities observed in the obese state, as 
suggested by Schreyer et al. (2003). 
In the present study, the differences found for lipid 
parameters, body mass index and blood pressure 
according to apo E genotypes were not conclusive. 
Mainly for E2 and E3 genotype subgroups, these 
discrepancies could be related to the statistical 
power decurrent from a bigger sample size than 
for the other subgroups. Anyway, these 
discrepancies are in agreement with the strong 
evidence that weight loss reduces blood pressure 
and serum triglycerides levels, increases HDL-
cholesterol concentration and generally leads to a 
reduction in total and in LDL-cholesterol levels in 
serum (Expert Panel, 1998). Although not 
consensual, the apo E ε3/ε4 and ε4/ε4 genotypes 
have been reported to be related to higher systolic 
blood pressure suggesting that apo E 
polymorphism might be one cardiovascular risk 
factor per se (de Knijff et al., 1994; Uusitupa et 
al., 1994). As being so, the mechanisms 
responsible for hypertension in our subgroups 
might be complicated by comorbid conditions of 
obesity (Reckelhoff, 2001) and induced by various 
pressor agents, according to the National Institutes 
of Health (NIH, 1997). Thus, dislipidemia as well 
as hypertension conditions, whose incidence can 
increase with age (but with different expressions in 
females and males, as proposed by Reckelhoff, 
2001), should be taken into consideration in 
further epidemiological studies for clarifying apo 
E polymorphism and atherosclerosis (and related 
cardiovascular diseases) relationship. 
 
Final remarks 
One limitation of this study should be 
acknowledged. Reduced samples size, especially 
in a genetic association study can potentially 
increase the risk of a false positive association. 
Further population cohort studies are needed to 
confirm and validate (or not) these findings. 
Whatever the future brings, apo E 
genotype/phenotype determination in parallel with 
apo E plasma concentration are expected to yield 
useful clinical laboratory information (Siest et al., 
1995a; Dreon and Peroutka, 2001). Thus, the 
estimation of apo E genotypes will need to become 
fast, economical, and technically undemanding in 
order to allow the investigation concerning apo E 
polymorphism and atherosclerosis widely 
available. 
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RESUMO 
 
O principal objectivo deste estudo é o de pesquisar 
o efeito da insularidade nos polimorfismos da 
apolipoproteína (apo) E em indivíduos saudáveis 
do continente (Lisboa) e de Ponta Delgada (Ilha de 
S. Miguel, Arquipélago dos Açores). 
Adicionalmente, estudar a distribuição dos seus 
genótipos em doentes com aterosclerose da Ilha de 
S. Miguel. Em Lisboa, a distribuição dos 
genótipos da apo E foi a seguinte: ε3/ε3 > ε3/ε4 > 
ε2/ε3 > ε4/ε4, ao passo que em Ponta Delgada e 
independentemente da condição fisiológica foi: 
ε3/ε3 > ε2/ε3 > ε3/ε4. Distintas frequências 
genotípicas foram observadas entre homens e 
mulheres no grupo saudável de Ponta Delgada. O 
índice de massa corporal, hipertensão arterial e 
perfil lipídico, factores de risco associados ao 
processo aterosclerótico, revelaram algumas 
diferenças quando avaliados em função dos grupos 
alélicos. Neste estudo, os genótipos de risco da 
apo E, ε2/ε2 e ε2/ε4, não foram contabilizados. 
Curiosamente a proporção dos genótipos nas 
mulheres foi heterogénea nos 3 grupos estudados. 
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